883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer
Publication
, Conference
Randall, LM; O'Malley, DM; Monk, BJ; Coleman, RL; O'Cearbhaill, RE; Gaillard, S; Adams, S; Cappuccini, F; Huang, M; Chon, HS; Secord, AA ...
Published in: Annals of Oncology
September 2020
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2020
Volume
31
Start / End Page
S646 / S647
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Randall, L. M., O’Malley, D. M., Monk, B. J., Coleman, R. L., O’Cearbhaill, R. E., Gaillard, S., … Konstantinopoulos, P. (2020). 883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer. In Annals of Oncology (Vol. 31, pp. S646–S647). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.08.1022
Randall, L. M., D. M. O’Malley, B. J. Monk, R. L. Coleman, R. E. O’Cearbhaill, S. Gaillard, S. Adams, et al. “883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer.” In Annals of Oncology, 31:S646–47. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.1022.
Randall LM, O’Malley DM, Monk BJ, Coleman RL, O’Cearbhaill RE, Gaillard S, et al. 883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer. In: Annals of Oncology. Elsevier BV; 2020. p. S646–7.
Randall, L. M., et al. “883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer.” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S646–47. Crossref, doi:10.1016/j.annonc.2020.08.1022.
Randall LM, O’Malley DM, Monk BJ, Coleman RL, O’Cearbhaill RE, Gaillard S, Adams S, Cappuccini F, Huang M, Chon HS, Secord AA, Arora S, Keeton E, Gupta D, Samnotra V, Konstantinopoulos P. 883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer. Annals of Oncology. Elsevier BV; 2020. p. S646–S647.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2020
Volume
31
Start / End Page
S646 / S647
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis